Saturday 17 October 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%

Follow BSX

Alert me

Market cap: $64.0B
P/E: 17.9×
Fwd P/E: 17.8×
Dividend yield: —
F-score: 7/9
Altman Z: 5.41
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 10.04

Total sells 23.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	3	—	1	4	—	—
Sell	2	1	—	1	—	—	—	—	—	—	—	—

Insider Ownership 2.05%

Capital & Financial Ratios $m

Market Cap 63,970.00

Revenue 20,995.00

Net Income 3,668.00

Free Cash Flow 3,625.00

Net Debt 12,085.00

Current Ratio 1.24

Debt/Equity 0.50

P/E ratio 17.90

Fwd P/E 17.80

P/S ratio 3.11

P/B ratio 2.59

Past 5Y EPS Growth —

This Y EPS Growth 6.15%

Next Y EPS Growth 4.24%

Next Y revenue growth 5.56%

Next 5Y EPS Growth 6.88%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 11.61%

10-year low 10-year high

P/S against its own 10 years 1.88%

10-year low 10-year high

P/B against its own 10 years 1.51%

10-year low 10-year high

EV/Sales against its own 10 years 1.44%

10-year low 10-year high

EV/FCF against its own 10 years 1.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	865	414	1,965	539
Receivables	2,228	2,558	2,926	3,049
Inventory	2,484	2,810	2,943	3,235
Other	621	831	660	760
	6,514	6,920	8,794	7,972

	2023	2024	2025	Q'26
Payables	942	960	1,144	1,231
ST’ Debt	531	1,778	299	1,709
Other	814	887	795	732
	4,933	6,399	5,439	6,428

Compound Annual Growth %

	10y	5y	3y
Sales	10.38%	15.16%	16.54%
Cash Flow	20.70%	24.63%	43.76%
Earnings	0.00%	0.00%	65.27%
Book Value	14.50%	9.81%	11.67%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	5,203	5,442	—	—	—
’25	4,663	5,061	5,065	5,285	20,074
’24	3,856	4,120	4,209	4,562	16,747
’23	3,389	3,599	3,527	3,725	14,240
’22	3,026	3,244	3,170	3,242	12,682
’21	2,752	3,077	2,932	3,127	11,888
’20	2,543	2,003	2,659	2,708	9,913

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	348	1,474	—	—	—
’25	541	1,286	1,343	1,364	4,534
’24	164	813	1,002	1,456	3,435
’23	190	658	698	957	2,503
’22	(58)	307	470	807	1,526
’21	284	643	465	478	1,870
’20	(77)	269	643	673	1,508

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	171	1,279	—	—	—
’25	354	1,129	1,162	1,013	3,658
’24	(15)	658	823	1,179	2,645
’23	82	515	509	686	1,792
’22	(171)	203	321	597	950
’21	213	540	361	216	1,330
’20	(174)	202	596	520	1,144

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.90	0.61	—	—	—
’25	0.45	0.53	0.51	0.45	1.94
’24	0.33	0.22	0.32	0.38	1.25
’23	0.21	0.18	0.34	0.34	1.07
’22	0.07	0.17	0.12	0.09	0.45
’21	0.23	0.12	0.28	0.06	0.69
’20	0.01	(0.11)	(0.12)	0.10	(0.12)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	15.67	21.66	24.84	32.73	24.10	34.58	34.98	44.35	57.11	85.98	Analyst estimates 2026–2028 Powerpack
	High	24.79	29.93	39.44	46.62	46.13	46.29	47.95	58.34	91.93	109.50
People
People	Employees	27,000	29,000	32,000	36,000	38,000	41,000	45,000	48,000	53,000	59,000
	Revenue/emp, $m	0.31	0.31	0.31	0.30	0.26	0.29	0.28	0.30	0.32	0.34
Income, $m
Income, $m	Revenue	8,386	9,048	9,823	10,735	9,913	11,888	12,682	14,240	16,747	20,074
	Gross margin, %	71.09	71.34	71.36	70.97	65.05	68.78	68.81	69.49	68.61	69.01
	EBT	177	933	1,422	687	(79)	1,076	1,141	1,985	2,282	3,385
	EBT margin, %	2.11	10.31	14.48	6.40	(0.80)	9.05	9.00	13.94	13.63	16.86
	Net income	347	104	1,671	4,700	(82)	1,041	698	1,592	1,846	2,892
	Depreciation	826	848	929	1,116	1,656	1,463	1,268	1,254	1,655	1,414
Per share, $
Per share, $	Revenue	6.18	6.60	7.11	7.71	7.00	8.36	8.87	9.80	11.38	13.56
	Earnings	0.26	0.08	1.21	3.38	(0.12)	0.69	0.45	1.08	1.26	1.96
	Cash flow	0.87	1.04	0.22	1.32	1.06	1.31	1.07	1.72	2.33	3.06
	Capex	(0.26)	(0.23)	(0.22)	(0.33)	(0.26)	(0.38)	(0.40)	(0.49)	(0.54)	(0.59)
	Free cash flow	0.62	0.81	0.01	0.99	0.81	0.94	0.66	1.23	1.80	2.47
	Book value	4.96	5.12	6.32	9.97	10.82	11.69	12.28	13.44	14.95	16.53
	Shares, m	1,358	1,370	1,381	1,392	1,417	1,422	1,431	1,453	1,472	1,480
Valuation, ×
Valuation, ×	P/E	84.15	316.00	29.21	13.38	0.00	61.57	102.24	54.06	70.89	48.65
	P/S	3.54	3.83	4.97	5.86	5.14	5.08	5.19	5.90	7.85	7.03
	P/B	4.41	4.94	5.59	4.53	3.32	3.63	3.75	4.30	5.97	5.77
	EV/Sales	4.17	4.43	5.67	6.77	5.89	5.68	5.82	6.48	8.47	7.50
	EV/FCF	41.91	36.19	6,964.32	52.62	51.00	50.80	77.71	51.49	53.60	41.18
Cash, $m
Cash, $m	Operating cash flow	1,182	1,426	310	1,836	1,508	1,870	1,526	2,503	3,435	4,534
	Capex	(347)	(319)	(302)	(454)	(364)	(540)	(576)	(711)	(790)	(876)
	Free cash flow	835	1,107	8	1,382	1,144	1,330	950	1,792	2,645	3,658
Balance, $m
Balance, $m	Working capital	(348)	(1,832)	(1,257)	(167)	3,013	2,043	1,957	1,581	521	3,355
	Total debt	5,484	5,616	7,056	10,008	9,143	9,065	8,935	9,102	10,746	11,436
	Net debt	5,288	5,428	6,910	9,791	7,409	7,140	8,007	8,237	10,332	9,471
	Shareholders’ equity	6,733	7,012	8,726	13,877	15,326	16,622	17,573	19,530	22,003	24,472
Returns, %
Returns, %	ROA	1.92	0.56	8.35	18.23	(0.37)	3.13	1.98	4.64	4.97	6.98
	ROIC	2.32	6.46	6.02	4.01	(0.22)	3.15	4.02	5.27	5.04	6.65
	ROE	5.32	1.51	21.24	41.59	(0.79)	6.17	3.75	8.46	8.92	12.47

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABT Abbott Laboratories	$181.1B	33.9×	22.9×	+13.02% (above 0%: growing)	−47.52% (below 0%: shrinking)	+28.87% (above 0%: growing)	57.71%	13.44%	Compare
MDT Medtronic PLC	$122.1B	23.2×	18.7×	+13.73% (above 0%: growing)	+41.98% (above 0%: growing)	+120.89% (above 0%: growing)	64.99%	18.08%	Compare
SYK Stryker Corporation	$112.5B	30.3×	24.1×	+9.42% (above 0%: growing)	+43.10% (above 0%: growing)	+14.12% (above 0%: growing)	68.27%	25.18%	Compare
BSX Boston Scientific Corporation	$64.0B	17.9×	17.8×	+7.53% (above 0%: growing)	+14.81% (above 0%: growing)	+13.29% (above 0%: growing)	70.71%	21.65%
EW Edwards Lifesciences Corporation	$50.8B	49.8×	30.7×	+13.63% (above 0%: growing)	−26.32% (below 0%: shrinking)	+142.84% (above 0%: growing)	77.46%	29.48%	Compare
DXCM DexCom, Inc.	$33.1B	33.2×	29.8×	+13.08% (above 0%: growing)	+41.30% (above 0%: growing)	−11.68% (below 0%: shrinking)	63.44%	24.33%	Compare
GEHC GE HealthCare Technologies Inc.	$31.8B	16.0×	14.4×	+5.75% (above 0%: growing)	+16.98% (above 0%: growing)	+750.00% (above 0%: growing)	41.17%	13.96%	Compare
PHG Koninklijke Philips N.V.	$24.9B	18.8×	11.2×	+2.94% (above 0%: growing)	+56.67% (above 0%: growing)	+49.74% (above 0%: growing)	49.31%	13.99%	Compare
STE STERIS plc	$21.9B	27.1×	23.6×	+7.30% (above 0%: growing)	+13.89% (above 0%: growing)	−14.36% (below 0%: shrinking)	45.84%	19.15%	Compare
Median of peers	$41.9B	28.7×	23.3×	+11.22%	+29.14%	+39.31%	60.58%	18.61%

All 149 Medical Devices stocks →

Boston Scientific Corporation (BSX) key facts

Strength: Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
Boston Scientific Corporation (BSX) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, BSX traded at $44.39, a market capitalization of $64.0 billion.
Return on equity was 12.5% and debt-to-equity 0.50.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 5.41 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.